#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=MicroRNAs ( miRNAs ) are a class of non-coding single-stranded RNA molecules encoded by endogenous genes of approximately 20 to 24 nucleotide ( nt ) in length .
2-1	16-25	MicroRNAs	abstract	new	coref	2-6[4_0]
2-2	26-27	(	_	_	_	_
2-3	28-34	miRNAs	abstract	new	coref	3-2
2-4	35-36	)	_	_	_	_
2-5	37-40	are	_	_	_	_
2-6	41-42	a	abstract[4]	giv[4]	_	_
2-7	43-48	class	abstract[4]	giv[4]	_	_
2-8	49-51	of	abstract[4]	giv[4]	_	_
2-9	52-62	non-coding	abstract[4]|object[6]	giv[4]|new[6]	_	_
2-10	63-78	single-stranded	abstract[4]|object[6]	giv[4]|new[6]	_	_
2-11	79-82	RNA	abstract[4]|substance|object[6]	giv[4]|new|new[6]	coref	5-20
2-12	83-92	molecules	abstract[4]|object[6]	giv[4]|new[6]	_	_
2-13	93-100	encoded	_	_	_	_
2-14	101-103	by	_	_	_	_
2-15	104-114	endogenous	abstract[7]	new[7]	_	_
2-16	115-120	genes	abstract[7]	new[7]	_	_
2-17	121-123	of	abstract[7]	new[7]	_	_
2-18	124-137	approximately	abstract[7]|quantity[8]	new[7]|new[8]	coref	8-14[0_8]
2-19	138-140	20	abstract[7]|quantity[8]	new[7]|new[8]	_	_
2-20	141-143	to	abstract[7]	new[7]	_	_
2-21	144-146	24	abstract[7]|quantity[9]	new[7]|new[9]	appos	2-24[0_9]
2-22	147-157	nucleotide	abstract[7]|quantity[9]	new[7]|new[9]	_	_
2-23	158-159	(	_	_	_	_
2-24	160-162	nt	quantity	giv	_	_
2-25	163-164	)	_	_	_	_
2-26	165-167	in	_	_	_	_
2-27	168-174	length	quantity	new	coref	8-19
2-28	175-176	.	_	_	_	_

#Text=Since miRNAs were first discovered in Caenorhabditis elegans , more and more miRNAs have been identified in humans , animals , plants and viruses .
3-1	177-182	Since	_	_	_	_
3-2	183-189	miRNAs	abstract	giv	coref	3-10[14_0]
3-3	190-194	were	_	_	_	_
3-4	195-200	first	_	_	_	_
3-5	201-211	discovered	_	_	_	_
3-6	212-214	in	_	_	_	_
3-7	215-229	Caenorhabditis	abstract	new	_	_
3-8	230-237	elegans	_	_	_	_
3-9	238-239	,	_	_	_	_
3-10	240-244	more	abstract[14]	giv[14]	coref	4-10[0_14]
3-11	245-248	and	abstract[14]	giv[14]	_	_
3-12	249-253	more	abstract[14]	giv[14]	_	_
3-13	254-260	miRNAs	abstract[14]	giv[14]	_	_
3-14	261-265	have	_	_	_	_
3-15	266-270	been	_	_	_	_
3-16	271-281	identified	_	_	_	_
3-17	282-284	in	_	_	_	_
3-18	285-291	humans	person	new	_	_
3-19	292-293	,	_	_	_	_
3-20	294-301	animals	animal	new	_	_
3-21	302-303	,	_	_	_	_
3-22	304-310	plants	plant	new	_	_
3-23	311-314	and	_	_	_	_
3-24	315-322	viruses	abstract	new	coref	15-1
3-25	323-324	.	_	_	_	_

#Text=With the advance in miRNA research , the way miRNAs are produced and function is well clarified .
4-1	325-329	With	_	_	_	_
4-2	330-333	the	abstract[19]	new[19]	_	_
4-3	334-341	advance	abstract[19]	new[19]	_	_
4-4	342-344	in	abstract[19]	new[19]	_	_
4-5	345-350	miRNA	abstract[19]|abstract|abstract[21]	new[19]|new|new[21]	coref	5-4
4-6	351-359	research	abstract[19]|abstract[21]	new[19]|new[21]	_	_
4-7	360-361	,	_	_	_	_
4-8	362-365	the	abstract[22]	new[22]	_	_
4-9	366-369	way	abstract[22]	new[22]	_	_
4-10	370-376	miRNAs	abstract	giv	coref	13-31
4-11	377-380	are	_	_	_	_
4-12	381-389	produced	_	_	_	_
4-13	390-393	and	_	_	_	_
4-14	394-402	function	abstract	new	coref	14-18
4-15	403-405	is	_	_	_	_
4-16	406-410	well	_	_	_	_
4-17	411-420	clarified	_	_	_	_
4-18	421-422	.	_	_	_	_

#Text=The maturity of miRNA includes the following stages : First , the non-coding region of DNA is transcribed by RNA polymerase I to form a precursor transcript ( primary miRNA , pri-miRNA ) with a hat structure ( 7MGpppG ) and a poly(A ) tail .
5-1	423-426	The	abstract[25]	new[25]	_	_
5-2	427-435	maturity	abstract[25]	new[25]	_	_
5-3	436-438	of	abstract[25]	new[25]	_	_
5-4	439-444	miRNA	abstract[25]|place	new[25]|giv	coref	6-19
5-5	445-453	includes	_	_	_	_
5-6	454-457	the	abstract[27]	new[27]	_	_
5-7	458-467	following	abstract[27]	new[27]	_	_
5-8	468-474	stages	abstract[27]	new[27]	_	_
5-9	475-476	:	_	_	_	_
5-10	477-482	First	_	_	_	_
5-11	483-484	,	_	_	_	_
5-12	485-488	the	place[28]	new[28]	_	_
5-13	489-499	non-coding	place[28]	new[28]	_	_
5-14	500-506	region	place[28]	new[28]	_	_
5-15	507-509	of	place[28]	new[28]	_	_
5-16	510-513	DNA	place[28]|substance	new[28]|new	_	_
5-17	514-516	is	_	_	_	_
5-18	517-528	transcribed	_	_	_	_
5-19	529-531	by	_	_	_	_
5-20	532-535	RNA	substance	giv	_	_
5-21	536-546	polymerase	object	new	_	_
5-22	547-548	I	person	acc	_	_
5-23	549-551	to	_	_	_	_
5-24	552-556	form	_	_	_	_
5-25	557-558	a	abstract[33]	new[33]	appos	5-29[34_33]
5-26	559-568	precursor	abstract[33]	new[33]	_	_
5-27	569-579	transcript	abstract[33]	new[33]	_	_
5-28	580-581	(	_	_	_	_
5-29	582-589	primary	abstract[34]	giv[34]	_	_
5-30	590-595	miRNA	abstract[34]	giv[34]	_	_
5-31	596-597	,	_	_	_	_
5-32	598-607	pri-miRNA	abstract	new	coref	6-1[41_0]
5-33	608-609	)	_	_	_	_
5-34	610-614	with	_	_	_	_
5-35	615-616	a	abstract[37]	new[37]	appos	5-39[0_37]
5-36	617-620	hat	object|abstract[37]	new|new[37]	_	_
5-37	621-630	structure	abstract[37]	new[37]	_	_
5-38	631-632	(	_	_	_	_
5-39	633-640	7MGpppG	abstract	giv	coref	6-25[48_0]
5-40	641-642	)	_	_	_	_
5-41	643-646	and	_	_	_	_
5-42	647-648	a	animal[39]|object[40]	new[39]|new[40]	_	_
5-43	649-655	poly(A	animal[39]|object[40]	new[39]|new[40]	_	_
5-44	656-657	)	object[40]	new[40]	_	_
5-45	658-662	tail	object[40]	new[40]	_	_
5-46	663-664	.	_	_	_	_

#Text=The pri-miRNA is then subjected to cleavage by RNase III nuclease Drosha and cofactor Pasha to generate a miRNA precursor ( pre-miRNA ) with a hairpin structure of approximately 70 – 90 nt .
6-1	665-668	The	abstract[41]	giv[41]	_	_
6-2	669-678	pri-miRNA	abstract[41]	giv[41]	_	_
6-3	679-681	is	_	_	_	_
6-4	682-686	then	_	_	_	_
6-5	687-696	subjected	_	_	_	_
6-6	697-699	to	_	_	_	_
6-7	700-708	cleavage	event[42]	new[42]	_	_
6-8	709-711	by	event[42]	new[42]	_	_
6-9	712-717	RNase	event[42]	new[42]	_	_
6-10	718-721	III	_	_	_	_
6-11	722-730	nuclease	_	_	_	_
6-12	731-737	Drosha	_	_	_	_
6-13	738-741	and	_	_	_	_
6-14	742-750	cofactor	person	new	_	_
6-15	751-756	Pasha	_	_	_	_
6-16	757-759	to	_	_	_	_
6-17	760-768	generate	_	_	_	_
6-18	769-770	a	object[45]	new[45]	_	_
6-19	771-776	miRNA	abstract|object[45]	giv|new[45]	coref	8-10[56_0]
6-20	777-786	precursor	object[45]	new[45]	_	_
6-21	787-788	(	_	_	_	_
6-22	789-798	pre-miRNA	substance	new	coref	7-1
6-23	799-800	)	_	_	_	_
6-24	801-805	with	_	_	_	_
6-25	806-807	a	abstract[48]	giv[48]	_	_
6-26	808-815	hairpin	place|abstract[48]	new|giv[48]	_	_
6-27	816-825	structure	abstract[48]	giv[48]	_	_
6-28	826-828	of	abstract[48]	giv[48]	_	_
6-29	829-842	approximately	abstract[48]|quantity[50]	giv[48]|new[50]	_	_
6-30	843-845	70	abstract[48]|quantity[50]	giv[48]|new[50]	_	_
6-31	846-847	–	abstract[48]|quantity[50]	giv[48]|new[50]	_	_
6-32	848-850	90	abstract[48]|quantity|quantity[50]	giv[48]|new|new[50]	_	_
6-33	851-853	nt	abstract[48]|quantity[50]	giv[48]|new[50]	_	_
6-34	854-855	.	_	_	_	_

#Text=Pre-miRNA is exported to the cytoplasm by RanGTP-dependent exportin 5 .
7-1	856-865	Pre-miRNA	substance	giv	coref	8-3[55_0]
7-2	866-868	is	_	_	_	_
7-3	869-877	exported	_	_	_	_
7-4	878-880	to	_	_	_	_
7-5	881-884	the	place[52]	new[52]	coref	10-10[76_52]
7-6	885-894	cytoplasm	place[52]	new[52]	_	_
7-7	895-897	by	_	_	_	_
7-8	898-914	RanGTP-dependent	person|abstract[54]	new|new[54]	_	_
7-9	915-923	exportin	abstract[54]	new[54]	_	_
7-10	924-925	5	abstract[54]	new[54]	_	_
7-11	926-927	.	_	_	_	_

#Text=Subsequently , the pre-miRNA is hydrolyzed and digested into a double-stranded miRNA of 20 to 24 nt in length , which consists of a guide strand miRNA and an incompletely complementary passenger strand miRNA* .
8-1	928-940	Subsequently	_	_	_	_
8-2	941-942	,	_	_	_	_
8-3	943-946	the	substance[55]	giv[55]	_	_
8-4	947-956	pre-miRNA	substance[55]	giv[55]	_	_
8-5	957-959	is	_	_	_	_
8-6	960-970	hydrolyzed	_	_	_	_
8-7	971-974	and	_	_	_	_
8-8	975-983	digested	_	_	_	_
8-9	984-988	into	_	_	_	_
8-10	989-990	a	abstract[56]	giv[56]	coref	8-24[61_56]
8-11	991-1006	double-stranded	abstract[56]	giv[56]	_	_
8-12	1007-1012	miRNA	abstract[56]	giv[56]	_	_
8-13	1013-1015	of	abstract[56]	giv[56]	_	_
8-14	1016-1018	20	abstract[56]|quantity	giv[56]|giv	_	_
8-15	1019-1021	to	_	_	_	_
8-16	1022-1024	24	quantity[58]	new[58]	_	_
8-17	1025-1027	nt	quantity[58]	new[58]	_	_
8-18	1028-1030	in	quantity[58]	new[58]	_	_
8-19	1031-1037	length	quantity[58]|quantity	new[58]|giv	_	_
8-20	1038-1039	,	_	_	_	_
8-21	1040-1045	which	_	_	_	_
8-22	1046-1054	consists	_	_	_	_
8-23	1055-1057	of	_	_	_	_
8-24	1058-1059	a	place[60]|abstract[61]	new[60]|giv[61]	coref|coref	8-29[63_60]|9-8[0_61]
8-25	1060-1065	guide	place[60]|abstract[61]	new[60]|giv[61]	_	_
8-26	1066-1072	strand	place[60]|abstract[61]	new[60]|giv[61]	_	_
8-27	1073-1078	miRNA	abstract[61]	giv[61]	_	_
8-28	1079-1082	and	_	_	_	_
8-29	1083-1085	an	place[63]	giv[63]	coref	9-8[69_63]
8-30	1086-1098	incompletely	place[63]	giv[63]	_	_
8-31	1099-1112	complementary	place[63]	giv[63]	_	_
8-32	1113-1122	passenger	person|place[63]	new|giv[63]	_	_
8-33	1123-1129	strand	place[63]	giv[63]	_	_
8-34	1130-1136	miRNA*	place[63]	giv[63]	_	_
8-35	1137-1138	.	_	_	_	_

#Text=The duplex is unwounded by helicase and miRNA guide strand then combined with the RNA-induced silencing complex ( RISC ) to recognize the target gene .
9-1	1139-1142	The	object[64]	new[64]	_	_
9-2	1143-1149	duplex	object[64]	new[64]	_	_
9-3	1150-1152	is	_	_	_	_
9-4	1153-1162	unwounded	_	_	_	_
9-5	1163-1165	by	_	_	_	_
9-6	1166-1174	helicase	substance|animal[66]	new|new[66]	ana	13-4[0_66]
9-7	1175-1178	and	animal[66]	new[66]	_	_
9-8	1179-1184	miRNA	animal[66]|abstract|place[69]	new[66]|giv|giv[69]	coref|coref	10-1[74_69]|11-1[77_0]
9-9	1185-1190	guide	animal[66]|object|place[69]	new[66]|new|giv[69]	_	_
9-10	1191-1197	strand	animal[66]|place[69]	new[66]|giv[69]	_	_
9-11	1198-1202	then	_	_	_	_
9-12	1203-1211	combined	_	_	_	_
9-13	1212-1216	with	_	_	_	_
9-14	1217-1220	the	abstract[71]	new[71]	_	_
9-15	1221-1232	RNA-induced	abstract|abstract[71]	new|new[71]	_	_
9-16	1233-1242	silencing	abstract[71]	new[71]	_	_
9-17	1243-1250	complex	abstract[71]	new[71]	_	_
9-18	1251-1252	(	_	_	_	_
9-19	1253-1257	RISC	event	new	_	_
9-20	1258-1259	)	_	_	_	_
9-21	1260-1262	to	_	_	_	_
9-22	1263-1272	recognize	_	_	_	_
9-23	1273-1276	the	abstract[73]	new[73]	coref	11-5[78_73]
9-24	1277-1283	target	abstract[73]	new[73]	_	_
9-25	1284-1288	gene	abstract[73]	new[73]	_	_
9-26	1289-1290	.	_	_	_	_

#Text=The passenger strand miRNA* is usually rapidly degraded in the cytoplasm .
10-1	1291-1294	The	place[74]|abstract[75]	giv[74]|new[75]	_	_
10-2	1295-1304	passenger	place[74]|abstract[75]	giv[74]|new[75]	_	_
10-3	1305-1311	strand	place[74]|abstract[75]	giv[74]|new[75]	_	_
10-4	1312-1318	miRNA*	abstract[75]	new[75]	_	_
10-5	1319-1321	is	_	_	_	_
10-6	1322-1329	usually	_	_	_	_
10-7	1330-1337	rapidly	_	_	_	_
10-8	1338-1346	degraded	_	_	_	_
10-9	1347-1349	in	_	_	_	_
10-10	1350-1353	the	place[76]	giv[76]	_	_
10-11	1354-1363	cytoplasm	place[76]	giv[76]	_	_
10-12	1364-1365	.	_	_	_	_

#Text=The mature miRNA recognizes the target gene through the 3′UTR of the target gene mRNA .
11-1	1366-1369	The	abstract[77]	giv[77]	coref	12-2[82_77]
11-2	1370-1376	mature	abstract[77]	giv[77]	_	_
11-3	1377-1382	miRNA	abstract[77]	giv[77]	_	_
11-4	1383-1393	recognizes	_	_	_	_
11-5	1394-1397	the	abstract[78]	giv[78]	coref	11-14[0_78]
11-6	1398-1404	target	abstract[78]	giv[78]	_	_
11-7	1405-1409	gene	abstract[78]	giv[78]	_	_
11-8	1410-1417	through	_	_	_	_
11-9	1418-1421	the	abstract[79]	new[79]	_	_
11-10	1422-1427	3′UTR	abstract[79]	new[79]	_	_
11-11	1428-1430	of	abstract[79]	new[79]	_	_
11-12	1431-1434	the	abstract[79]	new[79]	_	_
11-13	1435-1441	target	abstract[79]	new[79]	_	_
11-14	1442-1446	gene	abstract|abstract[81]	giv|new[81]	coref|coref	12-9[83_81]|13-37
11-15	1447-1451	mRNA	abstract[81]	new[81]	_	_
11-16	1452-1453	.	_	_	_	_

#Text=When the mature miRNA is fully complementary to the target mRNA , the target mRNA will be degraded .
12-1	1454-1458	When	_	_	_	_
12-2	1459-1462	the	abstract[82]	giv[82]	_	_
12-3	1463-1469	mature	abstract[82]	giv[82]	_	_
12-4	1470-1475	miRNA	abstract[82]	giv[82]	_	_
12-5	1476-1478	is	_	_	_	_
12-6	1479-1484	fully	_	_	_	_
12-7	1485-1498	complementary	_	_	_	_
12-8	1499-1501	to	_	_	_	_
12-9	1502-1505	the	abstract[83]	giv[83]	coref	12-13[84_83]
12-10	1506-1512	target	abstract[83]	giv[83]	_	_
12-11	1513-1517	mRNA	abstract[83]	giv[83]	_	_
12-12	1518-1519	,	_	_	_	_
12-13	1520-1523	the	abstract[84]	giv[84]	coref	13-14[88_84]
12-14	1524-1530	target	abstract[84]	giv[84]	_	_
12-15	1531-1535	mRNA	abstract[84]	giv[84]	_	_
12-16	1536-1540	will	_	_	_	_
12-17	1541-1543	be	_	_	_	_
12-18	1544-1552	degraded	_	_	_	_
12-19	1553-1554	.	_	_	_	_

#Text=However , if their sequences are not fully paired , the translation of the target mRNA will be inhibited and the integrity of the mRNA will not be affected . miRNAs have the broadest range of gene regulation and regulate a variety of biological processes , including early embryo development , cell proliferation and differentiation , apoptosis and death , viral infection and tumorigenesis .
13-1	1555-1562	However	_	_	_	_
13-2	1563-1564	,	_	_	_	_
13-3	1565-1567	if	_	_	_	_
13-4	1568-1573	their	animal|abstract[86]	giv|new[86]	_	_
13-5	1574-1583	sequences	abstract[86]	new[86]	_	_
13-6	1584-1587	are	_	_	_	_
13-7	1588-1591	not	_	_	_	_
13-8	1592-1597	fully	_	_	_	_
13-9	1598-1604	paired	_	_	_	_
13-10	1605-1606	,	_	_	_	_
13-11	1607-1610	the	event[87]	new[87]	_	_
13-12	1611-1622	translation	event[87]	new[87]	_	_
13-13	1623-1625	of	event[87]	new[87]	_	_
13-14	1626-1629	the	event[87]|abstract[88]	new[87]|giv[88]	coref	13-24[90_88]
13-15	1630-1636	target	event[87]|abstract[88]	new[87]|giv[88]	_	_
13-16	1637-1641	mRNA	event[87]|abstract[88]	new[87]|giv[88]	_	_
13-17	1642-1646	will	_	_	_	_
13-18	1647-1649	be	_	_	_	_
13-19	1650-1659	inhibited	_	_	_	_
13-20	1660-1663	and	_	_	_	_
13-21	1664-1667	the	abstract[89]	new[89]	_	_
13-22	1668-1677	integrity	abstract[89]	new[89]	_	_
13-23	1678-1680	of	abstract[89]	new[89]	_	_
13-24	1681-1684	the	abstract[89]|abstract[90]	new[89]|giv[90]	_	_
13-25	1685-1689	mRNA	abstract[89]|abstract[90]	new[89]|giv[90]	_	_
13-26	1690-1694	will	_	_	_	_
13-27	1695-1698	not	_	_	_	_
13-28	1699-1701	be	_	_	_	_
13-29	1702-1710	affected	_	_	_	_
13-30	1711-1712	.	_	_	_	_
13-31	1713-1719	miRNAs	abstract	giv	coref	17-6
13-32	1720-1724	have	_	_	_	_
13-33	1725-1728	the	abstract[92]	new[92]	_	_
13-34	1729-1737	broadest	abstract[92]	new[92]	_	_
13-35	1738-1743	range	abstract[92]	new[92]	_	_
13-36	1744-1746	of	abstract[92]	new[92]	_	_
13-37	1747-1751	gene	abstract[92]|abstract|abstract[94]	new[92]|giv|new[94]	_	_
13-38	1752-1762	regulation	abstract[92]|abstract[94]	new[92]|new[94]	_	_
13-39	1763-1766	and	_	_	_	_
13-40	1767-1775	regulate	_	_	_	_
13-41	1776-1777	a	abstract[95]	new[95]	_	_
13-42	1778-1785	variety	abstract[95]	new[95]	_	_
13-43	1786-1788	of	abstract[95]	new[95]	_	_
13-44	1789-1799	biological	abstract[95]|abstract[96]	new[95]|new[96]	_	_
13-45	1800-1809	processes	abstract[95]|abstract[96]	new[95]|new[96]	_	_
13-46	1810-1811	,	abstract[95]	new[95]	_	_
13-47	1812-1821	including	abstract[95]	new[95]	_	_
13-48	1822-1827	early	abstract[95]|event[98]	new[95]|new[98]	_	_
13-49	1828-1834	embryo	abstract[95]|substance|event[98]	new[95]|new|new[98]	_	_
13-50	1835-1846	development	abstract[95]|event[98]	new[95]|new[98]	_	_
13-51	1847-1848	,	abstract[95]	new[95]	_	_
13-52	1849-1853	cell	abstract[95]|place|event[100]	new[95]|new|new[100]	coref|coref	17-30|17-30[153_100]
13-53	1854-1867	proliferation	abstract[95]|event[100]	new[95]|new[100]	_	_
13-54	1868-1871	and	abstract[95]	new[95]	_	_
13-55	1872-1887	differentiation	abstract[95]|event	new[95]|new	_	_
13-56	1888-1889	,	abstract[95]	new[95]	_	_
13-57	1890-1899	apoptosis	abstract[95]|event	new[95]|new	_	_
13-58	1900-1903	and	abstract[95]	new[95]	_	_
13-59	1904-1909	death	abstract[95]|event	new[95]|new	coref	16-11
13-60	1910-1911	,	abstract[95]	new[95]	_	_
13-61	1912-1917	viral	abstract[95]|object|event[105]	new[95]|new|new[105]	coref	14-27[0_105]
13-62	1918-1927	infection	abstract[95]|event[105]	new[95]|new[105]	_	_
13-63	1928-1931	and	abstract[95]	new[95]	_	_
13-64	1932-1945	tumorigenesis	abstract[95]|abstract	new[95]|new	coref	17-26
13-65	1946-1947	.	_	_	_	_

#Text=Avian immunosuppressive disease refers to a series of infectious diseases that result in damage or loss of function to the immune system of the poultry after infection .
14-1	1948-1953	Avian	abstract[107]	new[107]	coref	15-8[120_107]
14-2	1954-1971	immunosuppressive	abstract[107]	new[107]	_	_
14-3	1972-1979	disease	abstract[107]	new[107]	_	_
14-4	1980-1986	refers	_	_	_	_
14-5	1987-1989	to	_	_	_	_
14-6	1990-1991	a	abstract[108]	new[108]	_	_
14-7	1992-1998	series	abstract[108]	new[108]	_	_
14-8	1999-2001	of	abstract[108]	new[108]	_	_
14-9	2002-2012	infectious	abstract[108]|abstract[109]	new[108]|new[109]	coref	16-30[142_109]
14-10	2013-2021	diseases	abstract[108]|abstract[109]	new[108]|new[109]	_	_
14-11	2022-2026	that	_	_	_	_
14-12	2027-2033	result	_	_	_	_
14-13	2034-2036	in	_	_	_	_
14-14	2037-2043	damage	abstract	new	_	_
14-15	2044-2046	or	_	_	_	_
14-16	2047-2051	loss	abstract[111]	new[111]	_	_
14-17	2052-2054	of	abstract[111]	new[111]	_	_
14-18	2055-2063	function	abstract[111]|abstract	new[111]|giv	_	_
14-19	2064-2066	to	_	_	_	_
14-20	2067-2070	the	abstract[113]	new[113]	_	_
14-21	2071-2077	immune	abstract[113]	new[113]	_	_
14-22	2078-2084	system	abstract[113]	new[113]	_	_
14-23	2085-2087	of	abstract[113]	new[113]	_	_
14-24	2088-2091	the	abstract[113]|animal[114]	new[113]|new[114]	_	_
14-25	2092-2099	poultry	abstract[113]|animal[114]	new[113]|new[114]	_	_
14-26	2100-2105	after	abstract[113]|animal[114]	new[113]|new[114]	_	_
14-27	2106-2115	infection	abstract[113]|animal[114]|event	new[113]|new[114]|giv	coref	16-1[133_0]
14-28	2116-2117	.	_	_	_	_

#Text=Viruses that cause immunosuppression in chickens include Marek ’s disease virus ( MDV ) , reticuloendotheliosis virus ( REV ) , avian leukosis virus ( ALV ) , infectious bursal disease virus ( IBDV ) , chicken infectious anemia virus ( CIAV ) and avian reovirus ( ARV ) .
15-1	2118-2125	Viruses	abstract	giv	coref	16-6[135_0]
15-2	2126-2130	that	_	_	_	_
15-3	2131-2136	cause	_	_	_	_
15-4	2137-2154	immunosuppression	abstract	new	coref	17-28
15-5	2155-2157	in	_	_	_	_
15-6	2158-2166	chickens	animal	new	coref	16-4[134_0]
15-7	2167-2174	include	_	_	_	_
15-8	2175-2180	Marek	person[119]|abstract[120]	new[119]|giv[120]	appos	15-13[0_120]
15-9	2181-2183	’s	person[119]|abstract[120]	new[119]|giv[120]	_	_
15-10	2184-2191	disease	abstract[120]	giv[120]	_	_
15-11	2192-2197	virus	abstract[120]	giv[120]	_	_
15-12	2198-2199	(	_	_	_	_
15-13	2200-2203	MDV	abstract	giv	coref	15-16[122_0]
15-14	2204-2205	)	_	_	_	_
15-15	2206-2207	,	_	_	_	_
15-16	2208-2229	reticuloendotheliosis	abstract[122]	giv[122]	appos	15-19[0_122]
15-17	2230-2235	virus	abstract[122]	giv[122]	_	_
15-18	2236-2237	(	_	_	_	_
15-19	2238-2241	REV	abstract	giv	coref	15-29[126_0]
15-20	2242-2243	)	_	_	_	_
15-21	2244-2245	,	_	_	_	_
15-22	2246-2251	avian	_	_	_	_
15-23	2252-2260	leukosis	_	_	_	_
15-24	2261-2266	virus	_	_	_	_
15-25	2267-2268	(	_	_	_	_
15-26	2269-2272	ALV	abstract	new	_	_
15-27	2273-2274	)	_	_	_	_
15-28	2275-2276	,	_	_	_	_
15-29	2277-2287	infectious	abstract[126]	giv[126]	appos	15-34[0_126]
15-30	2288-2294	bursal	event|abstract[126]	new|giv[126]	_	_
15-31	2295-2302	disease	abstract[126]	giv[126]	_	_
15-32	2303-2308	virus	abstract[126]	giv[126]	_	_
15-33	2309-2310	(	_	_	_	_
15-34	2311-2315	IBDV	abstract	giv	coref	15-37[129_0]
15-35	2316-2317	)	_	_	_	_
15-36	2318-2319	,	_	_	_	_
15-37	2320-2327	chicken	animal|abstract[129]	new|giv[129]	_	_
15-38	2328-2338	infectious	abstract[129]	giv[129]	_	_
15-39	2339-2345	anemia	abstract[129]	giv[129]	_	_
15-40	2346-2351	virus	abstract[129]	giv[129]	_	_
15-41	2352-2353	(	_	_	_	_
15-42	2354-2358	CIAV	organization	new	_	_
15-43	2359-2360	)	_	_	_	_
15-44	2361-2364	and	_	_	_	_
15-45	2365-2370	avian	person	new	_	_
15-46	2371-2379	reovirus	_	_	_	_
15-47	2380-2381	(	_	_	_	_
15-48	2382-2385	ARV	abstract	new	_	_
15-49	2386-2387	)	_	_	_	_
15-50	2388-2389	.	_	_	_	_

#Text=The infection of chickens with these viruses not only causes death , but also increases susceptibility to other microbial infections and the risk of failure in subsequent vaccination against other diseases , leading to serious economic losses .
16-1	2390-2393	The	event[133]	giv[133]	_	_
16-2	2394-2403	infection	event[133]	giv[133]	_	_
16-3	2404-2406	of	event[133]	giv[133]	_	_
16-4	2407-2415	chickens	event[133]|animal[134]	giv[133]|giv[134]	coref	17-19[148_134]
16-5	2416-2420	with	event[133]|animal[134]	giv[133]|giv[134]	_	_
16-6	2421-2426	these	event[133]|animal[134]|abstract[135]	giv[133]|giv[134]|giv[135]	_	_
16-7	2427-2434	viruses	event[133]|animal[134]|abstract[135]	giv[133]|giv[134]|giv[135]	_	_
16-8	2435-2438	not	_	_	_	_
16-9	2439-2443	only	_	_	_	_
16-10	2444-2450	causes	_	_	_	_
16-11	2451-2456	death	event	giv	_	_
16-12	2457-2458	,	_	_	_	_
16-13	2459-2462	but	_	_	_	_
16-14	2463-2467	also	_	_	_	_
16-15	2468-2477	increases	_	_	_	_
16-16	2478-2492	susceptibility	abstract[137]	new[137]	_	_
16-17	2493-2495	to	abstract[137]	new[137]	_	_
16-18	2496-2501	other	abstract[137]|abstract[138]	new[137]|new[138]	_	_
16-19	2502-2511	microbial	abstract[137]|abstract[138]	new[137]|new[138]	_	_
16-20	2512-2522	infections	abstract[137]|abstract[138]	new[137]|new[138]	_	_
16-21	2523-2526	and	abstract[137]	new[137]	_	_
16-22	2527-2530	the	abstract[137]|abstract[139]	new[137]|new[139]	ana	17-1[0_139]
16-23	2531-2535	risk	abstract[137]|abstract[139]	new[137]|new[139]	_	_
16-24	2536-2538	of	abstract[137]|abstract[139]	new[137]|new[139]	_	_
16-25	2539-2546	failure	abstract[137]|abstract[139]|event[140]	new[137]|new[139]|new[140]	_	_
16-26	2547-2549	in	abstract[137]|abstract[139]|event[140]	new[137]|new[139]|new[140]	_	_
16-27	2550-2560	subsequent	abstract[137]|abstract[139]|event[140]|event[141]	new[137]|new[139]|new[140]|new[141]	_	_
16-28	2561-2572	vaccination	abstract[137]|abstract[139]|event[140]|event[141]	new[137]|new[139]|new[140]|new[141]	_	_
16-29	2573-2580	against	abstract[137]|abstract[139]|event[140]|event[141]	new[137]|new[139]|new[140]|new[141]	_	_
16-30	2581-2586	other	abstract[137]|abstract[139]|event[140]|event[141]|abstract[142]	new[137]|new[139]|new[140]|new[141]|giv[142]	coref	17-21[149_142]
16-31	2587-2595	diseases	abstract[137]|abstract[139]|event[140]|event[141]|abstract[142]	new[137]|new[139]|new[140]|new[141]|giv[142]	_	_
16-32	2596-2597	,	_	_	_	_
16-33	2598-2605	leading	_	_	_	_
16-34	2606-2608	to	_	_	_	_
16-35	2609-2616	serious	abstract[143]	new[143]	_	_
16-36	2617-2625	economic	abstract[143]	new[143]	_	_
16-37	2626-2632	losses	abstract[143]	new[143]	_	_
16-38	2633-2634	.	_	_	_	_

#Text=It has been reported that miRNAs are involved in a number of regulatory activities in the response of chickens with avian immunosuppressive diseases , including tumorigenesis , immunosuppression , cell proliferation and viral replication .
17-1	2635-2637	It	abstract	giv	_	_
17-2	2638-2641	has	_	_	_	_
17-3	2642-2646	been	_	_	_	_
17-4	2647-2655	reported	_	_	_	_
17-5	2656-2660	that	_	_	_	_
17-6	2661-2667	miRNAs	abstract	giv	coref	18-8
17-7	2668-2671	are	_	_	_	_
17-8	2672-2680	involved	_	_	_	_
17-9	2681-2683	in	_	_	_	_
17-10	2684-2685	a	abstract[146]	new[146]	_	_
17-11	2686-2692	number	abstract[146]	new[146]	_	_
17-12	2693-2695	of	abstract[146]	new[146]	_	_
17-13	2696-2706	regulatory	abstract[146]	new[146]	_	_
17-14	2707-2717	activities	abstract[146]	new[146]	_	_
17-15	2718-2720	in	_	_	_	_
17-16	2721-2724	the	abstract[147]	new[147]	_	_
17-17	2725-2733	response	abstract[147]	new[147]	_	_
17-18	2734-2736	of	abstract[147]	new[147]	_	_
17-19	2737-2745	chickens	abstract[147]|animal[148]	new[147]|giv[148]	_	_
17-20	2746-2750	with	abstract[147]|animal[148]	new[147]|giv[148]	_	_
17-21	2751-2756	avian	abstract[147]|animal[148]|abstract[149]	new[147]|giv[148]|giv[149]	coref	18-15[160_149]
17-22	2757-2774	immunosuppressive	abstract[147]|animal[148]|abstract[149]	new[147]|giv[148]|giv[149]	_	_
17-23	2775-2783	diseases	abstract[147]|animal[148]|abstract[149]	new[147]|giv[148]|giv[149]	_	_
17-24	2784-2785	,	abstract[147]|animal[148]|abstract[149]	new[147]|giv[148]|giv[149]	_	_
17-25	2786-2795	including	abstract[147]|animal[148]|abstract[149]	new[147]|giv[148]|giv[149]	_	_
17-26	2796-2809	tumorigenesis	abstract[147]|animal[148]|abstract[149]|event	new[147]|giv[148]|giv[149]|giv	_	_
17-27	2810-2811	,	abstract[147]|animal[148]|abstract[149]	new[147]|giv[148]|giv[149]	_	_
17-28	2812-2829	immunosuppression	abstract[147]|animal[148]|abstract[149]|abstract	new[147]|giv[148]|giv[149]|giv	_	_
17-29	2830-2831	,	abstract[147]|animal[148]|abstract[149]	new[147]|giv[148]|giv[149]	_	_
17-30	2832-2836	cell	abstract[147]|animal[148]|abstract[149]|place|abstract[153]	new[147]|giv[148]|giv[149]|giv|giv[153]	_	_
17-31	2837-2850	proliferation	abstract[147]|animal[148]|abstract[149]|abstract[153]	new[147]|giv[148]|giv[149]|giv[153]	_	_
17-32	2851-2854	and	abstract[147]|animal[148]|abstract[149]	new[147]|giv[148]|giv[149]	_	_
17-33	2855-2860	viral	abstract[147]|animal[148]|abstract[149]|abstract[154]	new[147]|giv[148]|giv[149]|new[154]	_	_
17-34	2861-2872	replication	abstract[147]|animal[148]|abstract[149]|abstract[154]	new[147]|giv[148]|giv[149]|new[154]	_	_
17-35	2873-2874	.	_	_	_	_

#Text=In this review , the roles of miRNAs in the pathogenesis and control of different avian immunosuppressive diseases will be discussed , which may provide some clues to further understandings of pathogenesis of avian immunosuppressive diseases .
18-1	2875-2877	In	_	_	_	_
18-2	2878-2882	this	abstract[155]	new[155]	_	_
18-3	2883-2889	review	abstract[155]	new[155]	_	_
18-4	2890-2891	,	_	_	_	_
18-5	2892-2895	the	abstract[156]	new[156]	_	_
18-6	2896-2901	roles	abstract[156]	new[156]	_	_
18-7	2902-2904	of	abstract[156]	new[156]	_	_
18-8	2905-2911	miRNAs	abstract[156]|object	new[156]|giv	_	_
18-9	2912-2914	in	abstract[156]	new[156]	_	_
18-10	2915-2918	the	abstract[156]|abstract[158]	new[156]|new[158]	coref	18-32[163_158]
18-11	2919-2931	pathogenesis	abstract[156]|abstract[158]	new[156]|new[158]	_	_
18-12	2932-2935	and	abstract[156]	new[156]	_	_
18-13	2936-2943	control	abstract[156]|abstract[159]	new[156]|new[159]	_	_
18-14	2944-2946	of	abstract[156]|abstract[159]	new[156]|new[159]	_	_
18-15	2947-2956	different	abstract[156]|abstract[159]|abstract[160]	new[156]|new[159]|giv[160]	coref	18-34[164_160]
18-16	2957-2962	avian	abstract[156]|abstract[159]|abstract[160]	new[156]|new[159]|giv[160]	_	_
18-17	2963-2980	immunosuppressive	abstract[156]|abstract[159]|abstract[160]	new[156]|new[159]|giv[160]	_	_
18-18	2981-2989	diseases	abstract[156]|abstract[159]|abstract[160]	new[156]|new[159]|giv[160]	_	_
18-19	2990-2994	will	_	_	_	_
18-20	2995-2997	be	_	_	_	_
18-21	2998-3007	discussed	_	_	_	_
18-22	3008-3009	,	_	_	_	_
18-23	3010-3015	which	_	_	_	_
18-24	3016-3019	may	_	_	_	_
18-25	3020-3027	provide	_	_	_	_
18-26	3028-3032	some	abstract[161]	new[161]	_	_
18-27	3033-3038	clues	abstract[161]	new[161]	_	_
18-28	3039-3041	to	abstract[161]	new[161]	_	_
18-29	3042-3049	further	abstract[161]|abstract[162]	new[161]|new[162]	_	_
18-30	3050-3064	understandings	abstract[161]|abstract[162]	new[161]|new[162]	_	_
18-31	3065-3067	of	abstract[161]|abstract[162]	new[161]|new[162]	_	_
18-32	3068-3080	pathogenesis	abstract[161]|abstract[162]|abstract[163]	new[161]|new[162]|giv[163]	_	_
18-33	3081-3083	of	abstract[161]|abstract[162]|abstract[163]	new[161]|new[162]|giv[163]	_	_
18-34	3084-3089	avian	abstract[161]|abstract[162]|abstract[163]|abstract[164]	new[161]|new[162]|giv[163]|giv[164]	_	_
18-35	3090-3107	immunosuppressive	abstract[161]|abstract[162]|abstract[163]|abstract[164]	new[161]|new[162]|giv[163]|giv[164]	_	_
18-36	3108-3116	diseases	abstract[161]|abstract[162]|abstract[163]|abstract[164]	new[161]|new[162]|giv[163]|giv[164]	_	_
18-37	3117-3118	.	_	_	_	_
